Vascular endothelial growth factor and its receptor, Flt-1, in smokers andnon-smokers

Citation
Fm. Belgore et al., Vascular endothelial growth factor and its receptor, Flt-1, in smokers andnon-smokers, BR J BIOMED, 57(3), 2000, pp. 207-213
Citations number
38
Categorie Soggetti
Medical Research Diagnosis & Treatment
Journal title
BRITISH JOURNAL OF BIOMEDICAL SCIENCE
ISSN journal
09674845 → ACNP
Volume
57
Issue
3
Year of publication
2000
Pages
207 - 213
Database
ISI
SICI code
0967-4845(2000)57:3<207:VEGFAI>2.0.ZU;2-#
Abstract
Raised levels of plasma vascular endothelial growth factor (VEGF) are found in some cancers, diabetes, and certain other conditions, but levels of its receptor, soluble Flt-1 (sFlt-1), in these diseases have yet to be reporte d. We hypothesised that smoking would influence levels of these molecules. Consequently, we measured VEGF and sFlt-1 by enzyme-linked immunosorbent as say (ELISA) in plasma from 92 non-smokers and 35 smokers. No difference in VEGF was seen between the groups but, despite considerable overlap, sFlt-1 was significantly lower in smokers (P = 0.027). VEGF and sFlt-1 correlated strongly with each other (P <0.001). Although VEGF may arise from a number of cell types, including endothelial cells, the primary source of sFlt-1 is thought to be the endothelium; however, neither VEGF nor sFlt-1 correlated with levels of the endothelial cell activation/damage marker soluble throm bomodulin. Our data point to changes in levels of the VEGF receptor, sFlt-1 - but not VEGF itself - in smokers, which appears to be unrelated to endot helial cell function.